中文

2024-06-03

前沿速览019期| CAR-T治B淋 前沿览新知


01

CD20双特异性抗体可改善CD19 CAR-T治疗淋巴瘤和慢性淋巴细胞白血病(CLL)的应答:淋巴瘤细胞研究和CLL动物研究

CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models


第一作者:Brinkmann BJ


Blood (IF=20.3). 2024 May 28:blood.2023022682. 


全文网址:https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2023022682/516240/CD20-bispecific-antibodies-improve-response-to?redirectedFrom=fulltext

02

CAR-T细胞治疗继发性中枢神经系统淋巴瘤:一项多中心分析

Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis


第一作者:Alsouqi A


Am J Hematol (IF=12.8). 2024 May 20. 


全文网址:https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27354

03

循环抗CD19 CAR-T细胞及其群体的动力学对DLBCL患者预后的影响

Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients


第一作者:Martín-Martín L


Blood Cancer J (IF=12.8). 2024 May 17;14(1):83. 


全文网址:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101460/

04

造血细胞移植或CAR-T细胞治疗后第一年接种 SARS-CoV-2疫苗:一项前瞻性多中心观察性研究

SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study


第一作者:Hill JA


Clin Infect Dis (IF=11.8). 2024 May 27:ciae291. 


全文网址:https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciae291/7683259?redirectedFrom=fulltext&login=false

05

商业化Relma-cel治疗复发/难治性中枢神经系统淋巴瘤的真实世界经验:一项对中国患者的多中心回顾性分析

Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China


第一作者:Yu W


J Immunother Cancer (IF=10.9). 2024 May 27;12(5):e008553. 


全文网址:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/38802271/

06

CAR-T细胞疗法并发症的管理:一项欧洲血液和骨髓移植学会的报告

Management of complications of chimeric antigen receptor T-cell therapy: a report by the European Society of Blood and Marrow Transplantation


第一作者:Penack O


Haematologica (IF=10.1). 2024 May 30. 


全文网址:https://haematologica.org/article/view/haematol.2023.284810

07

CAR-T细胞疗法后的缓解:淋巴瘤患者能否恢复正常生活?

Remission after CAR T-cell therapy: Do lymphoma patients recover a normal life?


第一作者:Perthus A


Hemasphere (IF=9.1). 2024 May 27;8(5):e72. 


全文网址:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/38803454/

08

CAR-T细胞治疗大B细胞淋巴瘤进展后的治疗结局

Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy


第一作者:Iacoboni G


Hemasphere (IF=9.1). 2024 May 21;8(5):e62. 


全文网址:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/38774657/

09

Axicabtagene ciloleucel二线治疗早期复发或原发难治大B细胞淋巴瘤的真实世界经验

Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma


第一作者:Othman T


Br J Haematol (IF=6.5). 2024 May 26.  


全文网址:https://onlinelibrary.wiley.com/doi/10.1111/bjh.19521

10

CAR-T治疗继发性中枢神经系统淋巴瘤患者的结局:一项CIBMTR分析

Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis


第一作者:Epperla N


Br J Haematol (IF=6.5). 2024 May 26. 


全文网址:https://onlinelibrary.wiley.com/doi/10.1111/bjh.19569


免责声明:本资料为专业医学资料,旨在促进医药信息的沟通和交流,仅供医疗卫生专业人士参考;任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗,不能替代专业医学意见。


审批编号:NP-NHL-2024.6-3 valid until 2026.6


供稿与审核:临床开发与医学部